1. Home
  2. ADVM vs EPSN Comparison

ADVM vs EPSN Comparison

Compare ADVM & EPSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADVM
  • EPSN
  • Stock Information
  • Founded
  • ADVM 2006
  • EPSN 2005
  • Country
  • ADVM United States
  • EPSN Canada
  • Employees
  • ADVM N/A
  • EPSN N/A
  • Industry
  • ADVM Biotechnology: Biological Products (No Diagnostic Substances)
  • EPSN Oil & Gas Production
  • Sector
  • ADVM Health Care
  • EPSN Energy
  • Exchange
  • ADVM Nasdaq
  • EPSN Nasdaq
  • Market Cap
  • ADVM 119.6M
  • EPSN 139.0M
  • IPO Year
  • ADVM 2014
  • EPSN N/A
  • Fundamental
  • Price
  • ADVM $4.25
  • EPSN $6.24
  • Analyst Decision
  • ADVM Strong Buy
  • EPSN Strong Buy
  • Analyst Count
  • ADVM 6
  • EPSN 1
  • Target Price
  • ADVM $27.83
  • EPSN $7.00
  • AVG Volume (30 Days)
  • ADVM 217.5K
  • EPSN 28.1K
  • Earning Date
  • ADVM 11-04-2024
  • EPSN 11-06-2024
  • Dividend Yield
  • ADVM N/A
  • EPSN 4.04%
  • EPS Growth
  • ADVM N/A
  • EPSN N/A
  • EPS
  • ADVM N/A
  • EPSN 0.24
  • Revenue
  • ADVM $1,000,000.00
  • EPSN $31,145,315.00
  • Revenue This Year
  • ADVM N/A
  • EPSN N/A
  • Revenue Next Year
  • ADVM $1,342.84
  • EPSN $15.65
  • P/E Ratio
  • ADVM N/A
  • EPSN $26.06
  • Revenue Growth
  • ADVM N/A
  • EPSN N/A
  • 52 Week Low
  • ADVM $4.01
  • EPSN $4.70
  • 52 Week High
  • ADVM $29.70
  • EPSN $6.75
  • Technical
  • Relative Strength Index (RSI)
  • ADVM 29.33
  • EPSN 54.23
  • Support Level
  • ADVM $4.42
  • EPSN $6.24
  • Resistance Level
  • ADVM $5.11
  • EPSN $6.75
  • Average True Range (ATR)
  • ADVM 0.30
  • EPSN 0.26
  • MACD
  • ADVM 0.01
  • EPSN 0.02
  • Stochastic Oscillator
  • ADVM 21.05
  • EPSN 48.54

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

About EPSN Epsilon Energy Ltd. Common Share

Epsilon Energy Ltd is engaged in the acquisition, development, gathering, and production of natural gas and oil reserves. The operating segments of the company include Upstream segment activities including acquisition, development, and production of natural gas reserves on properties within the United States. The Gas Gathering segment partners with two other companies to operate a natural gas gathering system, and the corporate segment activities include corporate listing and governance functions of the corporation. The company generates revenue from the sale of crude oil and natural gas.

Share on Social Networks: